Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mutation Characterization and Heterodimer Analysis of Patients With Leukocyte Adhesion Deficiency: Including One Novel Mutation Publisher Pubmed



Teimourian S1, 2 ; De Boer M3 ; Roos D3 ; Isaian A4 ; Moghanloo E2, 5 ; Lashkary S1 ; Hassani B1 ; Mollanoori H1 ; Babaei V1 ; Azarnezhad A6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Genetics, Iran University of Medical Sciences IUMS, Tehran, Iran
  2. 2. Pediatric Infectious Diseases Research Center, Department of Infectious Diseases, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Sanquin Research, Karl Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
  4. 4. Department of Pathology, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  5. 5. Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran
  6. 6. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Cellular and Molecular Research Center, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Kurdistan, Iran

Source: Immunology Letters Published:2017


Abstract

Background and aim Leukocyte adhesion deficiency type 1 (LAD-I) is a rare, autosomal recessive disorder of neutrophil migration, characterized by severe, recurrent bacterial infections, inadequate pus formation and impaired wound healing. The ITGB2 gene encodes the β2 integrin subunit (CD18) of the leukocyte adhesion cell molecules, and mutations in this gene cause LAD-I. The aim of the current study was to investigate the mutations in patients diagnosed with LAD-I and functional studies of the impact of two previously reported and a novel mutation on the expression of the CD18/CD11a heterodimer. Materials and methods Blood samples were taken from three patients who had signed the consent form. Genomic DNA was extracted and ITGB2 exons and flanking intronic regions were amplified by polymerase chain reaction. Mutation screening was performed after Sanger sequencing of PCR products. For functional studies, COS-7 cells were co-transfected with an expression vector containing cDNA encoding mutant CD18 proteins and normal CD11a. Flow cytometry analysis of CD18/CD11a expression was assessed by dimer-specific IB4 monoclonal antibody. Results Two previously reported mutations and one novel mutation,p. Cys562Tyr, were found. All mutations reduced CD18/CD11 heterodimer expression. Conclusion Our strategy recognized the p.Cys562Tyr mutation as a pathogenic alteration that does not support CD18 heterodimer formation. Therefore, it can be put into a panel of carrier and prenatal diagnosis programs. © 2017 European Federation of Immunological Societies